56 related articles for article (PubMed ID: 38448401)
1. Blastic phase of chronic myelogenous leukemia.
Morris EL; Dutcher JP
Clin Adv Hematol Oncol; 2005 Jul; 3(7):547-52. PubMed ID: 16167037
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes of patients with lymphoid blastic phase of chronic myeloid leukemia treated with CAR T-cell therapy.
Liu Y; Tu Y; Xiao J; Shen Y; Zhou B; Yang Q; Yu L; Qi L; Chen J; Liu T; Wu D; Xu Y
Blood Cancer J; 2024 Mar; 14(1):39. PubMed ID: 38448401
[No Abstract] [Full Text] [Related]
3. Finding new lanes: Chimeric antigen receptor (CAR) T-cells for myeloid leukemia.
Pratap S; Zhao ZJ
Cancer Rep (Hoboken); 2020 Apr; 3(2):e1222. PubMed ID: 32671999
[TBL] [Abstract][Full Text] [Related]
4. [Outlook for cellular adoptive or vaccine immunotherapy for chronic myeloid leukemia].
Buzyn A; Ostankovitch M; Varet B; Guillet JG
Hematol Cell Ther; 1998 Oct; 40(5):222-3. PubMed ID: 9844815
[No Abstract] [Full Text] [Related]
5. Case report: CD38-directed CAR-T cell therapy: A novel immunotherapy targeting CD38- positive blasts overcomes TKI and chemotherapy resistance of myeloid chronic myeloid leukemia in blastic phase.
Cui Q; Liang P; Dai H; Cui W; Cai M; Ding Z; Ma Q; Yin J; Li Z; Liu S; Kang L; Yao L; Cen J; Shen H; Zhu M; Yu L; Wu D; Tang X
Front Immunol; 2022; 13():1012981. PubMed ID: 36524116
[TBL] [Abstract][Full Text] [Related]
6. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis.
Derderian PM; Kantarjian HM; Talpaz M; O'Brien S; Cork A; Estey E; Pierce S; Keating M
Am J Med; 1993 Jan; 94(1):69-74. PubMed ID: 8420302
[TBL] [Abstract][Full Text] [Related]
7. Long: molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapy.
Venkataraman V; Casey KS; Onozato M; Cin PD; Nardi V; Amrein PC; Bergeron MK; Brunner AM; Fathi AT; Foster JE; Moran J; Graubert TA; Hock H; Hunnewell C; Frigault MJ; McAfee S; Hobbs GS
Leukemia; 2020 Nov; 34(11):3050-3054. PubMed ID: 32678290
[No Abstract] [Full Text] [Related]
8. Embracing chimeric antigen receptors for relapsed chronic lymphocytic leukaemia.
Kamdar M
Lancet; 2023 Aug; 402(10402):590-592. PubMed ID: 37597880
[No Abstract] [Full Text] [Related]
9. Anti-CD19 CAR T-cell consolidation therapy combined with CD19+ feeding T cells and TKI for Ph+ acute lymphoblastic leukemia.
Chen LY; Gong WJ; Li MH; Zhou HX; Xu MZ; Qian CS; Kang LQ; Xu N; Yu Z; Qiao M; Zhang TT; Zhang L; Tian ZL; Sun AN; Yu L; Wu DP; Xue SL
Blood Adv; 2023 Sep; 7(17):4913-4925. PubMed ID: 36897251
[TBL] [Abstract][Full Text] [Related]
10. Treatment of CML-transformed B Cell Acute Lymphoblastic Leukemia (B-ALL) in Adults with Anti-CD19 Chimeric Antigen Receptor T Cell (CAR T) Therapy.
Liu F; Sha S; Ma G; Su Y; Xiong Y; He G; Li Y; Hanes WM; Tse W
Stem Cell Rev Rep; 2020 Dec; 16(6):1356-1358. PubMed ID: 32840736
[No Abstract] [Full Text] [Related]
11. Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for a Pediatric Ph-Like B-ALL Patient That Relapsed After CART-Cell and Haplo-HSCT Therapy: A Case Report and Review of Literature.
Hua J; Qian W; Wu X; Zhou L; Yu L; Chen S; Zhang J; Qiu H
Onco Targets Ther; 2020; 13():2311-2317. PubMed ID: 32256082
[TBL] [Abstract][Full Text] [Related]
12. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure.
Gauthier J; Hirayama AV; Purushe J; Hay KA; Lymp J; Li DH; Yeung CCS; Sheih A; Pender BS; Hawkins RM; Vakil A; Phi TD; Steinmetz RN; Shadman M; Riddell SR; Maloney DG; Turtle CJ
Blood; 2020 May; 135(19):1650-1660. PubMed ID: 32076701
[TBL] [Abstract][Full Text] [Related]
13. Durable Molecular Remission in a Lymphoid BP-CML Patient Harboring T315I Mutation Treated with Anti-CD19 CAR-T Therapy.
Zhou L; Shi H; Shi W; Yang L; Zhang Y; Xu M; Chen X; Zhu Y; Mu H; Wan X; Yang Z; Zeng Y; Liu H
Onco Targets Ther; 2019; 12():10989-10995. PubMed ID: 31997880
[TBL] [Abstract][Full Text] [Related]
14. The Principles of Engineering Immune Cells to Treat Cancer.
Lim WA; June CH
Cell; 2017 Feb; 168(4):724-740. PubMed ID: 28187291
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
